By Samantha Denefrio, PhD
What is it?
Aetion has created a software platform, the Aetion Evidence Platform, that uses real-world, big data to evaluate the effectiveness of medical interventions such as drugs or certain therapies. The FDA, large pharmaceutical companies, and insurance providers look to Aetion to help evaluate and validate the use and safety of their products.
Why is it innovative?
“The biggest innovation you can make is a better decision” (Aetion). Aetion’s platform seeks to increase the quality and quantity of data analysis behind many drugs, medical devices, and treatments on the market. They strive to provide transparent results to inform crucial decisions about the best treatment options that are both evidence-based and will provide the safest and most effective indications for use.
Recently, the FDA is working with Aetion’s data analytics platform to be able to predict the outcomes of clinical trials before they are completed (Fierce Biotech). The goal is to predict outcomes of seven Phase IV trials by using real-world data from insurance claims data sources. Aetion CEO Carolyn Magill said, “This project will play a major role in determining the future of how drugs are developed and approved. Data collected from the front lines of clinical care can often provide a more complete picture on how treatments affect patients not represented in clinical trials, but the regulatory process must ensure transparency” (PR Newswire).
These trials build on the RCT DUPLICATE program’s original scope to use real-world evidence to attempt to replicate the results of 30 completed randomized controlled trials. Overall, the RCT DUPLICATE project, which is managed by researchers at Brigham and Women’s Hospital/Harvard Medical School, will inform the FDA’s standards for using real-world evidence in regulatory decision-making.
“We help you answer the high-stakes questions in health care: which treatments work best, for whom, and when. Because better answers lead to better decisions” (Aetion).
Total Funding: $77 M since its 2015 launch
Facts Sheet and Details (Crunchbase)
News Stories on Aetion